DVL Brings in ￥100 Million in a Series B Round

(VCBeat) May. 6, 2021 -- DVL, a leading manufacturer of products for surgical hemostasis in China, announced the completion of a Series B financing, jointly led by Qingdao Shuimu Zijin, Qingdao Shuimu Ziteng, and Hainan Jinhuifeng, with a total amount of nearly 100 million yuan. Proceeds will be mainly used to promote product research and development, expand production lines and increase investment in marketing.

DVL was established in 2012 in China Medical City, Taizhou City, Jiangsu Province. With the sales team's nearly 8 years of professional experience in medical devices at home and abroad, and relying on the platform of the only national professional medical industrial park in China, DVL has quickly built an innovative R&D center for hemostatic materials that integrates R&D, production, registration service and sales. At present, DVL has obtained the registration certificate of four products, including "polyglycan materials for hemostasis", and "high-frequency surgical electroknife and electrode". The company also completed the product development in two fields of passive and active hemostatic materials, which has fully covered the field of hemostatic consumables used during the surgery.

DVL has a sales team with rich experience and strong execution in the industry. Within one year, DVL has built a sales network covering all provinces and regions in China. Relying on high-performance products, brand foundation and resource advantages, DVL has achieved rapid growth in sales performance. In the future, DVL will make further use of the industry-university-research resources to make valuable innovations. Combined with academic exchanges, basic education and training and other activities, DVL will launch new products to the market, so that the company's products can be accessible to more people in need and benefit their livelihood.

Currently, DVL has now started its Series C financing. The funds will be used to further expand the production of hemostatic materials, expand the market, at the same time build a large R&D center in Shanghai and set up a new production base. DVL plans to develop three to four high-end hemostatic products in the next two or three years to take up a larger share of the market, and become a leading enterprise of new hemostatic materials.